Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension
S. Harutyunova (Heidelberg, Germany), N. Benkamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), A. Marra (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Harutyunova (Heidelberg, Germany), N. Benkamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), A. Marra (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), E. Grünig (Heidelberg, Germany). Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension. 5463
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004
One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005
Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003
Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006
Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001
Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001
Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 1334-1335 Year: 2001
Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 18: 247 Year: 2001
Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006
Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management Year: 2017
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004
Successful artocoronary bypass grafting in a patient with severe idiopathic pulmonary arterial hypertension: use of intravenous treprostinil Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009